ArticleFrontiers in genetics2026
Episignature-based modelled first-tier diagnostic approach in the Dutch Caribbean: advancing equal care through epigenetic classification.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Access to advanced genetic testing in the Dutch Caribbean is limited due to financial and logistical constraints. As a result, many patients with rare disorders remain undiagnosed or receive uncertain results, leading to unequal genetic care. DNA methylation profiles, or episignatures, provide sensitive and specific biomarkers. The clinically validated EpiSign™ assay offers a cost-effective and rapid diagnostic approach. Methods: In this study, we evaluated EpiSign™ as a modelled first-tier screening approach within a proposed diagnostic workflow in a resource-limited setting and assessed its diagnostic yield and clinical utility in 19 patients from the Dutch Caribbean. Peripheral blood DNA was analyzed using the EPIC array, and methylation profiles were classified via a support vector machine algorithm against the EpiSign™ Knowledge Database. All patients underwent ID-WES and/or CGH-array analysis as part of the diagnostic workup. Positive EpiSign™ findings were subsequently confirmed by these molecular analyses. Results: EpiSign™ helped provide a clinical diagnosis for six cases, including Fragile X syndrome, Intellectual Developmental Disorder X-linked 93 (MRX93), ReNU syndrome, and Kleefstra syndrome 1, all confirmed by subsequent analyses. Several patients harbored variants of uncertain significance in genes not yet associated with known episignatures. Discussion: These results demonstrate that EpiSign™ provides actionable diagnostic insights as a first-tier diagnostic tool, particularly when combined with genomic analyses in the absence of parental samples. Its dynamic database allows reanalysis as new episignatures are identified, increasing its potential clinical utility in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.